Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: Its influence on FasL, TRAIL and their receptors on erythroblasts

Haematologica

Volumn 91, Issue 3, 2006, Pages 386-389

  Grzasko, Norbert ^a   Dmoszynska, Anna ^a   Hus, Marek ^a   Soroka Wojtaszko, Maria ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Anemia; FasL; Multiple myeloma; Thalidomide; TRAIL

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; FAS LIGAND; THALIDOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ERYTHROBLAST; ERYTHROPOIESIS; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; PROTEIN EXPRESSION;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; ERYTHROBLASTS; ERYTHROPOIESIS; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; THALIDOMIDE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 33645415687     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E, et al. Apoptotic role of Fas/Fas-ligand system in the regulation of erythropoiesis. Blood 1999;93:796-803.
2. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES, Guidotti L, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000;95:3716-24.
3. Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anaemia and disease progression. Blood 2001;97:1155-64.
4. Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenic mechanism of anaemia in multiple myeloma. Blood 2002;99:1305-13.
5. Singhal S, Metha J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refrectory multiple myeloma. N Engl J Med 1999;341:1565-71.
6. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
7. Dmoszynska A, Bojarska-Junak A, Domanski D, Rolinski J, Hus M, Soroka-Wojtaszko M. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002;43:401-6.
8. Rowland TL, McHough SM, Deighton J, Dearman RJ, Ewan PW. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripherial blood mononuclear cells. Immunopharmacology 1998;400:11-20.
9. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, et al. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol 2000;108:391-3.
10. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
11. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
12. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepluch H, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001;86:404-8.
13. Grzasko N, Dmoszynska A, Krawczyk S, Hus M, Soroka-Wojtaszko M, Ciepluch H, et al. Evaluation of blood morphology in patients with refractory multiple myeloma treated with thalidomide. Pol Arch Med Wewn 2001;106:573-9.
14. Zeldis JB, Williams BA, Thomas D, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319-30.
15. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001;86:399-403.
16. Kakimoto T, Hattori Y, Okamoto S, Sato N, Kamata T, Yamaguchi M, et al. Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res 2002;93:1029-36.
17. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Fidor A. Thalidomide monotherapy of patients with refractory and relapsed multiple myeloma. Acta Haematol Pol 2000;31:407-14.
18. Zappasodi P, Lorenzi A, Corso A. Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity. Haematologica 2001;86:448.
19. Corso A, Lorenzi A, Zappasodi P, Invernizzi R, Vanelli L, Lazzarino M. Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma. Haematologica 2003;88:958-960.